FNYS
CELG

First New York Securities’s Celgene Corp CELG Stock Holding History

First New York Securities’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,120
Closed -$78K – 501
2014
Q1 		$78K Buy
+1,120
New +$88.7K 0.04% 226

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First New York Securities's CELG Position: Q2 2014 in Review

First New York Securities sold out of Celgene Corp (CELG) in Q2 2014, closing a stake of 1,120 shares — an estimated $78K sold.

First New York Securities first reported a position in CELG in Q1 2014 and held it in 1 quarter. The position peaked at $78K in Q1 2014. 995 funds tracked by Wall St. Rank hold CELG as of Q2 2014.

  • First New York Securities reported no remaining Celgene Corp position as of Q2 2014 after selling out during the quarter.
  • First New York Securities sold 1,120 Celgene Corp shares in Q2 2014, an estimated $78K.
  • First New York Securities first reported a position in Celgene Corp in Q1 2014 and held it in 1 quarter.
  • First New York Securities's Celgene Corp position peaked at $78K in Q1 2014.
  • 995 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2014.

Based on First New York Securities's 13F filing for Q2 2014, filed 15 Aug 2014.